CL2012003090A1 - Formulacion farmaceutica topica que comprende heparina y por lo menos un ester polioxialquilenico de un acido hidroxi graso; y uso de la heparina para el tratamiento o prevencion de una complicacion funcional de fistulas a-v e injertos a-v en pacientes cronicos de hemodialisis. - Google Patents

Formulacion farmaceutica topica que comprende heparina y por lo menos un ester polioxialquilenico de un acido hidroxi graso; y uso de la heparina para el tratamiento o prevencion de una complicacion funcional de fistulas a-v e injertos a-v en pacientes cronicos de hemodialisis.

Info

Publication number
CL2012003090A1
CL2012003090A1 CL2012003090A CL2012003090A CL2012003090A1 CL 2012003090 A1 CL2012003090 A1 CL 2012003090A1 CL 2012003090 A CL2012003090 A CL 2012003090A CL 2012003090 A CL2012003090 A CL 2012003090A CL 2012003090 A1 CL2012003090 A1 CL 2012003090A1
Authority
CL
Chile
Prior art keywords
heparin
fistulas
grafts
prevention
treatment
Prior art date
Application number
CL2012003090A
Other languages
English (en)
Inventor
Michele Virno
Original Assignee
Lectio Pharmaentwicklungs Und Verwertungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003090(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lectio Pharmaentwicklungs Und Verwertungs Gmbh filed Critical Lectio Pharmaentwicklungs Und Verwertungs Gmbh
Publication of CL2012003090A1 publication Critical patent/CL2012003090A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2012003090A 2010-05-07 2012-11-06 Formulacion farmaceutica topica que comprende heparina y por lo menos un ester polioxialquilenico de un acido hidroxi graso; y uso de la heparina para el tratamiento o prevencion de una complicacion funcional de fistulas a-v e injertos a-v en pacientes cronicos de hemodialisis. CL2012003090A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2010A000816A IT1400232B1 (it) 2010-05-07 2010-05-07 Composizione farmaceutica topica comprendente eparina
US34762610P 2010-05-24 2010-05-24

Publications (1)

Publication Number Publication Date
CL2012003090A1 true CL2012003090A1 (es) 2014-01-03

Family

ID=43567710

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003090A CL2012003090A1 (es) 2010-05-07 2012-11-06 Formulacion farmaceutica topica que comprende heparina y por lo menos un ester polioxialquilenico de un acido hidroxi graso; y uso de la heparina para el tratamiento o prevencion de una complicacion funcional de fistulas a-v e injertos a-v en pacientes cronicos de hemodialisis.

Country Status (17)

Country Link
US (1) US20130102564A1 (es)
EP (1) EP2566457A1 (es)
JP (1) JP2013525505A (es)
KR (1) KR20130054286A (es)
CN (1) CN102946862A (es)
AR (1) AR082653A1 (es)
AU (1) AU2011250005B2 (es)
BR (1) BR112012028434A2 (es)
CA (1) CA2798116A1 (es)
CL (1) CL2012003090A1 (es)
EA (1) EA026568B1 (es)
IL (1) IL222790A0 (es)
IT (1) IT1400232B1 (es)
MX (1) MX2012012930A (es)
NZ (1) NZ603476A (es)
WO (1) WO2011138262A1 (es)
ZA (1) ZA201208949B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120009136A1 (en) * 2010-07-09 2012-01-12 The Dial Corporation Antiperspirant products comprising natural phospholipids and methods for manufacturing the same
CA2938388C (en) * 2014-02-10 2018-07-17 Troikaa Pharmaceuticals Limited Topical formulations of heparin
PL229532B1 (pl) * 2014-05-29 2018-07-31 Lipolek Spolka Z Ograniczona Odpowiedzialnoscia Żelowy preparat soli sodowej heparyny do podawania naskórnego

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) * 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
CA2201358C (en) 1994-09-30 2004-06-08 Jurgen Regenold Pharmaceutical composition
US5668119A (en) 1996-02-22 1997-09-16 Medenica; Rajko D. Topical pharmaceutical containing heparin and method of treatment
EP0946185B2 (en) * 1996-11-27 2010-05-05 Aventis Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
AU3625500A (en) * 1999-03-11 2000-09-28 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
CN1492759A (zh) * 2001-01-16 2004-04-28 Ѫ�������������ι�˾ 预防或治疗血液透析中血管通路和其它血管移植物故障的装置及方法
KR20040018333A (ko) * 2001-02-16 2004-03-03 시미즈 세이야꾸 가부시키가이샤 소장 전달용 점액다당류 함유 경구 제형, 및 순환 장애치료에서의 이들의 용도
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
WO2003066859A2 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
US8152750B2 (en) 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
US20050136103A1 (en) * 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
CA2734381A1 (en) * 2008-09-12 2010-03-18 Critical Pharmaceuticals Limited Improvements in the absorption of therapeutic agents across mucosal membranes or the skin

Also Published As

Publication number Publication date
EA026568B1 (ru) 2017-04-28
IL222790A0 (en) 2012-12-31
MX2012012930A (es) 2013-05-20
IT1400232B1 (it) 2013-05-24
EA201291191A1 (ru) 2013-04-30
AR082653A1 (es) 2012-12-26
AU2011250005B2 (en) 2015-08-13
KR20130054286A (ko) 2013-05-24
US20130102564A1 (en) 2013-04-25
NZ603476A (en) 2014-10-31
CA2798116A1 (en) 2011-11-10
ZA201208949B (en) 2013-07-31
AU2011250005A1 (en) 2012-11-29
EP2566457A1 (en) 2013-03-13
CN102946862A (zh) 2013-02-27
BR112012028434A2 (pt) 2019-09-24
ITMI20100816A1 (it) 2011-11-08
WO2011138262A1 (en) 2011-11-10
JP2013525505A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
IL280294A (en) A pharmaceutical preparation containing the phytocannabinoids cannabidiol (CBD) and cannabidiol (CBD)
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
CL2014000732A1 (es) Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
CL2012003290A1 (es) Metodo para preparar una composicion enriquecida en igg a partir de plasma; composicion acuosa de igg; composicion farmaceutica que comprende dicha composicion acuosa; uso de dicha composicion para tratar enfermedad autoinmune o infeccion aguda
CO6842016A2 (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer
SV2010003674A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
UY34358A (es) ?tratamiento de la esclerosis múltiple con una combinación de laquinimod y acetato de glatiramer?.
BR112013014189A2 (pt) composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
CL2013000513A1 (es) Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
BRPI0816264A2 (pt) composição farmacêutica que compreende a combinação de diversos agentes venotônicos e vasoprotetores para o tratamento da insuficiência venosa crônica
CL2014000267A1 (es) Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion.
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
BR112012019351A2 (pt) composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica.
CL2011002265A1 (es) Composicion farmaceutica que comprende simvastatina, enalapril y acido acetilsalicilico; uso para prevenir y tratar enfermedades cardiovasculares.
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição
IT1396468B1 (it) Uso topico di acido ialuronico ad azione filmogena in preparati per il trattamento e profilassi di patologie delle vie respiratorie.
CL2012003090A1 (es) Formulacion farmaceutica topica que comprende heparina y por lo menos un ester polioxialquilenico de un acido hidroxi graso; y uso de la heparina para el tratamiento o prevencion de una complicacion funcional de fistulas a-v e injertos a-v en pacientes cronicos de hemodialisis.
BRPI0913839A2 (pt) composição farmacêutica com glicosaminoglicanos e uso da mesma no tratamento de úlceras crônicas
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.